AU2005311191C1 - Antitumor combinations containing a VEGF inhibitor and 5FU or one of its derivatives - Google Patents

Antitumor combinations containing a VEGF inhibitor and 5FU or one of its derivatives Download PDF

Info

Publication number
AU2005311191C1
AU2005311191C1 AU2005311191A AU2005311191A AU2005311191C1 AU 2005311191 C1 AU2005311191 C1 AU 2005311191C1 AU 2005311191 A AU2005311191 A AU 2005311191A AU 2005311191 A AU2005311191 A AU 2005311191A AU 2005311191 C1 AU2005311191 C1 AU 2005311191C1
Authority
AU
Australia
Prior art keywords
trap
vegf
fluorouracil
combination
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2005311191A
Other languages
English (en)
Other versions
AU2005311191A1 (en
AU2005311191B2 (en
Inventor
Marie-Christine Bissery
Jesse M. Cedarbaum
Marielle Chiron-Blondel
Eric Furfine
Jocelyn Holash
Patricia Vrignaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Mature IP
Original Assignee
Sanofi Mature IP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2005311191(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Mature IP filed Critical Sanofi Mature IP
Publication of AU2005311191A1 publication Critical patent/AU2005311191A1/en
Application granted granted Critical
Publication of AU2005311191B2 publication Critical patent/AU2005311191B2/en
Publication of AU2005311191C1 publication Critical patent/AU2005311191C1/en
Assigned to SANOFI MATURE IP reassignment SANOFI MATURE IP Request for Assignment Assignors: AVENTIS PHARMA S.A.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2005311191A 2004-12-03 2005-12-02 Antitumor combinations containing a VEGF inhibitor and 5FU or one of its derivatives Expired AU2005311191C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0412870 2004-12-03
FR0412870A FR2878749B1 (fr) 2004-12-03 2004-12-03 Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
PCT/FR2005/003005 WO2006059012A1 (fr) 2004-12-03 2005-12-02 Combinaisons antitumorales contenant un agent inhibiteur de vegf et du 5fu ou un de ses derives

Publications (3)

Publication Number Publication Date
AU2005311191A1 AU2005311191A1 (en) 2006-06-08
AU2005311191B2 AU2005311191B2 (en) 2011-12-08
AU2005311191C1 true AU2005311191C1 (en) 2015-04-30

Family

ID=34954452

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005311191A Expired AU2005311191C1 (en) 2004-12-03 2005-12-02 Antitumor combinations containing a VEGF inhibitor and 5FU or one of its derivatives

Country Status (25)

Country Link
US (3) US20060178305A1 (enExample)
EP (1) EP1824504B1 (enExample)
JP (1) JP4980236B2 (enExample)
KR (1) KR101313404B1 (enExample)
CN (1) CN101068564B (enExample)
AT (1) ATE426409T1 (enExample)
AU (1) AU2005311191C1 (enExample)
BR (1) BRPI0518700B8 (enExample)
CA (1) CA2586735C (enExample)
CY (3) CY1109181T1 (enExample)
DE (1) DE602005013568D1 (enExample)
DK (1) DK1824504T3 (enExample)
ES (1) ES2324233T3 (enExample)
FR (3) FR2878749B1 (enExample)
HR (1) HRP20090336T1 (enExample)
IL (1) IL183481A (enExample)
LU (2) LU92202I2 (enExample)
ME (1) ME01706B (enExample)
MX (1) MX2007006607A (enExample)
PL (1) PL1824504T3 (enExample)
PT (1) PT1824504E (enExample)
RS (1) RS50769B (enExample)
RU (1) RU2384344C2 (enExample)
SI (1) SI1824504T1 (enExample)
WO (1) WO2006059012A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
RS58957B1 (sr) 2014-07-18 2019-08-30 Sanofi Sa Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
EP3246029A1 (en) * 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN115197948A (zh) * 2021-04-13 2022-10-18 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒rNDV-VEGF-Trap、其基因组、制备方法及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000895A2 (en) * 2003-06-30 2005-01-06 Regeneron Pharmaceuticals, Inc. Vegf traps and therapeutic uses thereof
US20050032699A1 (en) * 2003-07-25 2005-02-10 Jocelyn Holash Composition of a VEGF antagonist and an anti-proliferative agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU9701081D0 (en) * 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
CN101433715B (zh) * 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000895A2 (en) * 2003-06-30 2005-01-06 Regeneron Pharmaceuticals, Inc. Vegf traps and therapeutic uses thereof
US20050032699A1 (en) * 2003-07-25 2005-02-10 Jocelyn Holash Composition of a VEGF antagonist and an anti-proliferative agent

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANNON, Clinical Breast Cancer. 2003, vol. 3, no. 6, pages 357-377 *
BRAUN, A.H. ET AL., Cancer. 15 April 2004, vol. 100, no. 8, pages 1558-1577 *
HURWITZ. H. ET AL., New England Journal of Medicine. 3 June 2004, vol. 350, no. 23, pages 2335-2342 *
KABBINAVAR, F. ET AL., Journal of Clinical Oncology. 2003, vol. 21, no. 1, pages 60-65 *
KAKLAMANI, V.G. & GRADISHAR, W.J., Expert Review of Anti-Cancer Therapy. 2003, vol. 3, no. 2, pages 137-144 *

Also Published As

Publication number Publication date
SI1824504T1 (sl) 2009-08-31
MX2007006607A (es) 2007-07-25
KR101313404B1 (ko) 2013-10-01
ATE426409T1 (de) 2009-04-15
LU92203I2 (fr) 2013-11-15
PL1824504T3 (pl) 2009-08-31
US20060178305A1 (en) 2006-08-10
HK1114769A1 (en) 2008-11-14
AU2005311191A1 (en) 2006-06-08
CY2013018I1 (el) 2020-05-29
AU2005311191B2 (en) 2011-12-08
CN101068564A (zh) 2007-11-07
CA2586735C (fr) 2014-08-12
FR13C0025I1 (fr) 2013-05-24
LU92203I9 (enExample) 2019-01-15
WO2006059012A1 (fr) 2006-06-08
EP1824504A1 (fr) 2007-08-29
DE602005013568D1 (de) 2009-05-07
LU92202I9 (enExample) 2019-01-15
FR13C0024I1 (fr) 2013-05-24
ES2324233T3 (es) 2009-08-03
BRPI0518700B1 (pt) 2020-02-11
RS50769B (sr) 2010-08-31
FR2878749A1 (fr) 2006-06-09
CN101068564B (zh) 2010-12-15
IL183481A0 (en) 2007-09-20
US8388963B2 (en) 2013-03-05
BRPI0518700A2 (pt) 2008-12-02
KR20070091130A (ko) 2007-09-07
CY2013017I1 (el) 2014-07-02
CY1109181T1 (el) 2014-07-02
EP1824504B1 (fr) 2009-03-25
DK1824504T3 (da) 2009-07-20
ME01706B (me) 2010-08-31
US20090285841A1 (en) 2009-11-19
LU92202I2 (fr) 2013-11-15
CA2586735A1 (fr) 2006-06-08
RU2007123607A (ru) 2009-01-10
HRP20090336T1 (hr) 2009-07-31
JP4980236B2 (ja) 2012-07-18
PT1824504E (pt) 2009-06-25
IL183481A (en) 2013-09-30
FR2878749B1 (fr) 2007-12-21
US20130184205A1 (en) 2013-07-18
RU2384344C2 (ru) 2010-03-20
BRPI0518700B8 (pt) 2021-05-25
JP2008521866A (ja) 2008-06-26

Similar Documents

Publication Publication Date Title
US8388963B2 (en) Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof
US20190275147A1 (en) Antitumour combinations containing a vegf inhibiting agent and irinotecan
PT2752189T (pt) Utilização de anticorpos anti-fcev em combinação com quimioterpia para o tratamento de cancro da mama
Nanni et al. High metastatic efficiency of human sarcoma cells in Rag2/γc double knockout mice provides a powerful test system for antimetastatic targeted therapy
Bunn Jr et al. Combinations of three chemotherapeutic agents and two chemotherapeutic agents plus a targeted biologic agent in the treatment of advanced non–small-cell lung cancer
Kerbel et al. Antiangiogenic drugs as broadly effective chemosensitizing agents
HK1114769B (en) Antitumor combinations containing a vegf inhibitor and 5fu or one of its derivative
HK1141241A (en) Antitumour combinations containing a vegf inhibiting agent and irinotecan
HK1194298A (en) Antitumour combinations containing a vegf inhibiting agent and irinotecan
US20090196869A1 (en) Antitumor combinations containing taxane derivatives
Mishima et al. Sequential treatment with irinotecan and doxifluridine: Optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer
Cividalli et al. 825 Cell cycle effects of taxol in a murine tumour and its implications in radiosensitization

Legal Events

Date Code Title Description
MK24 Application lapsed reg. 22.2e(2) - failure to pay response fee
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY THE RESPONSE FEES HAS BEEN EXTENDED TO 21 JAN 2012.

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 10 OCT 2014 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 10 OCT 2014

ON Decision of a delegate or deputy of the commissioner of patents (result of patent office hearing)

Free format text: (2016) APO 34: DECISION: I REFUSE THE APPLICATION FOR AN EXTENSION OF THE TERM OF PATENT 2005311191.

Effective date: 20160610

NDR Extension of term of standard patents, section 70: refusal

Free format text: PRODUCT NAME: ZALTRAP AFLIBERCEPT

Filing date: 20130402

PC Assignment registered

Owner name: SANOFI MATURE IP

Free format text: FORMER OWNER(S): AVENTIS PHARMA S.A.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired